The estimated efficiency of pneumococcal vaccination in able-bodied men
Брико Н. И., Батyршина Л. Р., Брико А. Н.
Профилактическая медицина
Т. 21, Вып. 3, С. 10-15
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.17116/profmed201821310
Аннотация:
Objective - to evaluate the possible epidemiological and economic efficiency of pneumococcal vaccination in men with different chronic diseases. Material and methods. A prognostic (Markov) model was constructed based on the data available in the literature. The estimated efficiency of pneumococcal vaccination in reducing mortality, preventable diseases, and economic damage over a 5-year period was evaluated in able-bodied men. According to official statistics, the group at high risk for pneumonia in the Russian Federation includes 21,575,887 able-bodied men. The sources of data on the cost of the disease were governmental tariffs in the compulsory health insurance system in 2016 and those of vaccination cost were the results of competitive bidding for the procurement of 13-valent pneumococcal conjugate vaccine (PCV13). Results. The results of extrapolation of data from Russian and foreign studies in patients with chronic respiratory diseases, circulatory diseases, or diabetes mellitus
Ключевые слова:
Chronic obstructive pulmonary disease; Coronary heart disease; Economic efficiency; Mortality; Vaccination
Язык текста: Русский
ISSN: 2309-513X
Брико Н. И. Николай Иванович 1953-
Батyршина Л. Р.
Брико А. Н.
Briko N. I. Nikolay Ivanovich 1953-
Batyrshina L. R.
Briko A. N.
The estimated efficiency of pneumococcal vaccination in able-bodied men
Текст визуальный непосредственный
Профилактическая медицина
Издательство Медиа Сфера
Т. 21, Вып. 3 С. 10-15
2018
Статья
Chronic obstructive pulmonary disease Coronary heart disease Economic efficiency Mortality Vaccination
Objective - to evaluate the possible epidemiological and economic efficiency of pneumococcal vaccination in men with different chronic diseases. Material and methods. A prognostic (Markov) model was constructed based on the data available in the literature. The estimated efficiency of pneumococcal vaccination in reducing mortality, preventable diseases, and economic damage over a 5-year period was evaluated in able-bodied men. According to official statistics, the group at high risk for pneumonia in the Russian Federation includes 21,575,887 able-bodied men. The sources of data on the cost of the disease were governmental tariffs in the compulsory health insurance system in 2016 and those of vaccination cost were the results of competitive bidding for the procurement of 13-valent pneumococcal conjugate vaccine (PCV13). Results. The results of extrapolation of data from Russian and foreign studies in patients with chronic respiratory diseases, circulatory diseases, or diabetes mellitus